297 related articles for article (PubMed ID: 28538184)
1. Taxane-Platin-Resistant Lung Cancers Co-develop Hypersensitivity to JumonjiC Demethylase Inhibitors.
Dalvi MP; Wang L; Zhong R; Kollipara RK; Park H; Bayo J; Yenerall P; Zhou Y; Timmons BC; Rodriguez-Canales J; Behrens C; Mino B; Villalobos P; Parra ER; Suraokar M; Pataer A; Swisher SG; Kalhor N; Bhanu NV; Garcia BA; Heymach JV; Coombes K; Xie Y; Girard L; Gazdar AF; Kittler R; Wistuba II; Minna JD; Martinez ED
Cell Rep; 2017 May; 19(8):1669-1684. PubMed ID: 28538184
[TBL] [Abstract][Full Text] [Related]
2. JumonjiC demethylase inhibitors show potential for targeting chemotherapy-resistant lung cancers.
Dalvi MP; Martinez ED
Mol Cell Oncol; 2017; 4(5):e1345352. PubMed ID: 29057307
[TBL] [Abstract][Full Text] [Related]
3. A small molecule modulates Jumonji histone demethylase activity and selectively inhibits cancer growth.
Wang L; Chang J; Varghese D; Dellinger M; Kumar S; Best AM; Ruiz J; Bruick R; Peña-Llopis S; Xu J; Babinski DJ; Frantz DE; Brekken RA; Quinn AM; Simeonov A; Easmon J; Martinez ED
Nat Commun; 2013; 4():2035. PubMed ID: 23792809
[TBL] [Abstract][Full Text] [Related]
4. Jumonji Inhibitors Overcome Radioresistance in Cancer through Changes in H3K4 Methylation at Double-Strand Breaks.
Bayo J; Tran TA; Wang L; Peña-Llopis S; Das AK; Martinez ED
Cell Rep; 2018 Oct; 25(4):1040-1050.e5. PubMed ID: 30355483
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic potential of GSK-J4, a histone demethylase KDM6B/JMJD3 inhibitor, for acute myeloid leukemia.
Li Y; Zhang M; Sheng M; Zhang P; Chen Z; Xing W; Bai J; Cheng T; Yang FC; Zhou Y
J Cancer Res Clin Oncol; 2018 Jun; 144(6):1065-1077. PubMed ID: 29594337
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of demethylase KDM6B sensitizes diffuse large B-cell lymphoma to chemotherapeutic drugs.
Mathur R; Sehgal L; Havranek O; Köhrer S; Khashab T; Jain N; Burger JA; Neelapu SS; Davis RE; Samaniego F
Haematologica; 2017 Feb; 102(2):373-380. PubMed ID: 27742770
[TBL] [Abstract][Full Text] [Related]
7. Elevating H3K27me3 level sensitizes colorectal cancer to oxaliplatin.
Wang Q; Chen X; Jiang Y; Liu S; Liu H; Sun X; Zhang H; Liu Z; Tao Y; Li C; Hu Y; Liu D; Ye D; Liu Y; Wang M; Zhang X
J Mol Cell Biol; 2020 Feb; 12(2):125-137. PubMed ID: 31065671
[TBL] [Abstract][Full Text] [Related]
8. Epigenomic profiling of non-small cell lung cancer xenografts uncover LRP12 DNA methylation as predictive biomarker for carboplatin resistance.
Grasse S; Lienhard M; Frese S; Kerick M; Steinbach A; Grimm C; Hussong M; Rolff J; Becker M; Dreher F; Schirmer U; Boerno S; Ramisch A; Leschber G; Timmermann B; Grohé C; Lüders H; Vingron M; Fichtner I; Klein S; Odenthal M; Büttner R; Lehrach H; Sültmann H; Herwig R; Schweiger MR
Genome Med; 2018 Jul; 10(1):55. PubMed ID: 30029672
[TBL] [Abstract][Full Text] [Related]
9. Small molecules targeting histone demethylase genes (KDMs) inhibit growth of temozolomide-resistant glioblastoma cells.
Banelli B; Daga A; Forlani A; Allemanni G; Marubbi D; Pistillo MP; Profumo A; Romani M
Oncotarget; 2017 May; 8(21):34896-34910. PubMed ID: 28432280
[TBL] [Abstract][Full Text] [Related]
10. SMARCA4 deficient tumours are vulnerable to KDM6A/UTX and KDM6B/JMJD3 blockade.
Romero OA; Vilarrubi A; Alburquerque-Bejar JJ; Gomez A; Andrades A; Trastulli D; Pros E; Setien F; Verdura S; Farré L; Martín-Tejera JF; Llabata P; Oaknin A; Saigi M; Piulats JM; Matias-Guiu X; Medina PP; Vidal A; Villanueva A; Sanchez-Cespedes M
Nat Commun; 2021 Jul; 12(1):4319. PubMed ID: 34262032
[TBL] [Abstract][Full Text] [Related]
11. Specific kinesin expression profiles associated with taxane resistance in basal-like breast cancer.
Tan MH; De S; Bebek G; Orloff MS; Wesolowski R; Downs-Kelly E; Budd GT; Stark GR; Eng C
Breast Cancer Res Treat; 2012 Feb; 131(3):849-58. PubMed ID: 21479552
[TBL] [Abstract][Full Text] [Related]
12. A comprehensive study of epigenetic alterations in hepatocellular carcinoma identifies potential therapeutic targets.
Bayo J; Fiore EJ; Dominguez LM; Real A; Malvicini M; Rizzo M; Atorrasagasti C; García MG; Argemi J; Martinez ED; Mazzolini GD
J Hepatol; 2019 Jul; 71(1):78-90. PubMed ID: 30880225
[TBL] [Abstract][Full Text] [Related]
13. Disruption of the
Matthews KA; Senagbe KM; Nötzel C; Gonzales CA; Tong X; Rijo-Ferreira F; Bhanu NV; Miguel-Blanco C; Lafuente-Monasterio MJ; Garcia BA; Kafsack BFC; Martinez ED
ACS Infect Dis; 2020 May; 6(5):1058-1075. PubMed ID: 32272012
[TBL] [Abstract][Full Text] [Related]
14. JIB-04, a Pan-Inhibitor of Histone Demethylases, Targets Histone-Lysine-Demethylase-Dependent AKT Pathway, Leading to Cell Cycle Arrest and Inhibition of Cancer Stem-Like Cell Properties in Hepatocellular Carcinoma Cells.
Lee J; Kim JS; Cho HI; Jo SR; Jang YK
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887001
[TBL] [Abstract][Full Text] [Related]
15. Inhibitors of Jumonji C domain-containing histone lysine demethylases overcome cisplatin and paclitaxel resistance in non-small cell lung cancer through APC/Cdh1-dependent degradation of CtIP and PAF15.
Duan L; Perez RE; Calhoun S; Maki CG
Cancer Biol Ther; 2022 Dec; 23(1):65-75. PubMed ID: 35100078
[TBL] [Abstract][Full Text] [Related]
16. Targeting P16INK4A in uterine serous carcinoma through inhibition of histone demethylation.
Xiao Z; He Y; Liu C; Xiang L; Yi J; Wang M; Shen T; Shen L; Xue Y; Shi H; Liu P
Oncol Rep; 2019 May; 41(5):2667-2678. PubMed ID: 30896884
[TBL] [Abstract][Full Text] [Related]
17. KDM2A promotes lung tumorigenesis by epigenetically enhancing ERK1/2 signaling.
Wagner KW; Alam H; Dhar SS; Giri U; Li N; Wei Y; Giri D; Cascone T; Kim JH; Ye Y; Multani AS; Chan CH; Erez B; Saigal B; Chung J; Lin HK; Wu X; Hung MC; Heymach JV; Lee MG
J Clin Invest; 2013 Dec; 123(12):5231-46. PubMed ID: 24200691
[TBL] [Abstract][Full Text] [Related]
18. Targeted inhibition of histone H3K27 demethylation is effective in high-risk neuroblastoma.
Lochmann TL; Powell KM; Ham J; Floros KV; Heisey DAR; Kurupi RIJ; Calbert ML; Ghotra MS; Greninger P; Dozmorov M; Gowda M; Souers AJ; Reynolds CP; Benes CH; Faber AC
Sci Transl Med; 2018 May; 10(441):. PubMed ID: 29769286
[TBL] [Abstract][Full Text] [Related]
19. Regulation of eIF4F Translation Initiation Complex by the Peptidyl Prolyl Isomerase FKBP7 in Taxane-resistant Prostate Cancer.
Garrido MF; Martin NJ; Bertrand M; Gaudin C; Commo F; El Kalaany N; Al Nakouzi N; Fazli L; Del Nery E; Camonis J; Perez F; Lerondel S; Le Pape A; Compagno D; Gleave M; Loriot Y; Désaubry L; Vagner S; Fizazi K; Chauchereau A
Clin Cancer Res; 2019 Jan; 25(2):710-723. PubMed ID: 30322877
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory/resistant nonsmall cell lung carcinoma.
Kim ES; Kies MS; Fossella FV; Glisson BS; Zaknoen S; Statkevich P; Munden RF; Summey C; Pisters KM; Papadimitrakopoulou V; Tighiouart M; Rogatko A; Khuri FR
Cancer; 2005 Aug; 104(3):561-9. PubMed ID: 16028213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
